PRKAA2 and obesity disorder: We have previously demonstrated in human primary skeletal muscle myotubes that 6 h of treatment with 0.1 μg/mL of globular adiponectin (gAd) increased AMPK activity in myotubes derived from lean individuals but only the higher dose of 0.5 μg/mL of gAd increased AMPK activity derived from individuals with obesity and obesity and diabetes [20].